Related Experiment Video
Updated: Jul 22, 2026

Severe Burn Injury in a Swine Model for Clinical Dressing Assessment
Published on: November 6, 2018
The use of growth hormone in the treatment of extensive burns: a case report
J Koller1, Z Marinov, K Kvalteni
1Ruzinov General Hospital, Bratislava, Slovakia.
Insights
Recombinant human growth hormone aided healing in a severe pediatric burn case. This anabolic hormone promoted recovery, with manageable side effects like mild insulinoresistance.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Pediatric Burn Care
Background:
- Growth hormone (GH) is a key anabolic hormone influencing cell growth and metabolism.
- Previous studies suggest GH benefits pediatric burn treatment.
- Severe burns present significant challenges in patient recovery and healing.
Observation:
- A 12-year-old boy experienced an extensive electrical arc burn (81% Total Body Surface Area, 60% full thickness).
- Treatment included recombinant human growth hormone (rhGH) at 0.52 IU/kg/day for 15 days, starting on post-burn day 19.
- The patient underwent intensive care, surgical procedures (excision and grafting), and supportive therapies.
Findings:
- rhGH administration was well-tolerated, with only mild insulinoresistance observed.
- Insulinoresistance was effectively managed by adjusting insulin dosage in glucose solutions.
- The majority of the patient's burns healed within 56 days of intensive care.
Implications:
- This case highlights the potential of rhGH as an adjunctive therapy for severe pediatric burns.
- GH treatment may improve healing outcomes and reduce recovery time in critically burned children.
- Further research is warranted to establish optimal rhGH dosing and long-term effects in pediatric burn patients.
Abstract:
Growth hormone is an anabolic hormone that causes increased cell growth, positive nitrogen and calcium balance, lipolysis, hyperglycemia, and promotes protein synthesis. Its beneficial effect in burn treatment was proven particularly in children, by Herndon's group. The authors report The case of a 12-year-old boy with an electrical arc burn of 81% of the BSA, 60% of the BSA being full thickness loss. Recombinant human growth hormone (Norditropin, Novo Nordisk) was administered at daily doses of 0.52 i.u./kg starting on day 19 post-burn for 15 consecutive days. The treatment was well tolerated except for mild insulinoresistance, which could be easily corrected by slightly increasing the insulin added to glucose solutions. After 56 days of intensive care treatment and several excision and grafting procedures, the majority of burns were healed.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Hypoglycemia and Glucagon

